アブストラクト
| Title | 骨粗鬆症治療薬の有効性と位置づけ |
|---|---|
| Subtitle | 特集 健康寿命延伸のための最新知識 サルコペニア×フレイル×骨粗鬆症の予防と治療 骨粗鬆症の治療と二次性骨折予防 |
| Authors | 岩本潤 |
| Authors (kana) | |
| Organization | 慶友整形外科病院骨関節疾患センター |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 2 |
| Page | 288-293 |
| Year/Month | 2023 / 2 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Key Point」●閉経後骨粗鬆症に対しては, 基本的には, 骨吸収抑制薬(経口製剤)が第一選択薬であり, 点滴・静注ビスホスホネートや皮下注デノスマブなどの注射製剤は代替薬である. ●70歳未満では椎体骨折の抑制効果のある薬剤が, 70歳以上では椎体骨折および大腿骨近位部骨折の抑制効果のある薬剤がよい適応となる. ●骨折の危険性の高い骨粗鬆症に対しては, 骨形成促進薬の適応があり, 骨形成促進薬で治療後は, 骨吸収抑制薬への逐次療法を行う. ●各薬剤の安全性や骨折抑制効果に加えて, 患者の年齢, 骨折リスク, アドヒアランス(治療継続の可能性)などを考慮し, 薬剤選択を考えることが重要である. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) 骨粗鬆症の予防と治療ガイドライン作成委員会・編 : 骨粗鬆症の予防と治療ガイドライン 2015年版. 日本骨粗鬆症学会・日本骨代謝学会, 2015
- 2) Sakuma M, et al : Incidence and outcome of osteoporotic fractures in 2004 in Sado City, Niigata Prefecture, Japan. J Bone Miner Metab, 26 : 373-378, 2008
- 3) Cauley JA, et al : Risk of mortality following clinical fractures. Osteoporos Int, 11 : 556-561, 2000
- 4) Klotzbuecher CM, et al : Patients with prior fractures have an increased risk of future fractures : a summary of the literature and statistical synthesis. J Bone Miner Res, 15 : 721-739, 2000
- 5) Kanis JA, et al : Executive summary of European guidance for the diagnosis and management of osteoporosis in post-menopausal women. Aging Clin Exp Res, 31 : 15-17, 2019
残りの20件を表示する
- 6) Compston JE, et al : Osteoporosis. Lancet, 393 : 364-376, 2019
- 7) Bone HG, et al : Effects of denosumab treatment and discon-tinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab, 96 : 972-980, 2011
- 8) Anastasilakis AD, et al : Clinical Features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation : systematic review and additional cases. J Bone Miner Res, 32 : 1291-1296, 2017
- 9) McClung MR. Cancel the denosumab holiday. Osteoporos Int, 27 : 1677-1682, 2016
- 10) McClung MR, et al : Observations following discontinuation of long-term denosumab therapy. Osteoporos Int, 28 : 1723-1732, 2017
- 11) Lorentzon M : Treating osteoporosis to prevent fractures : current concepts and future developments. J Intern Med, 285 : 381-394, 2019
- 12) Kanis JA, et al : Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. Kanis JA. Osteoporos Int, 31 : 1-12, 2020
- 13) Neer RM, et al : Effect of parathyroid hormone(1-34)on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 344 : 1434-1441, 2001
- 14) Nakamura T, et al : Randomized Teriparatide[human parathyroid hormone(PTH)1-34]Once-Weekly Efficacy Research(TOWER)trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. J Clin Endocrinol Metab, 97 : 3097-3106, 2012
- 15) Sugimoto T, et al : Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients : the TWICE study. Osteoporos Int, 30 : 2321-2331, 2019
- 16) Leder BZ, et al : Denosumab and teriparatide transitions in postmenopausal osteoporosis(the DATA-Switch study) : extension of a randomised controlled trial. Lancet, 386 : 1147-1155, 2015
- 17) Lindsay R, et al : Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med, 164 : 2024-2030, 2004
- 18) Sugimoto T, et al : Vertebral fracture risk after once-weekly teriparatide injections : follow-up study of Teriparatide Once-Weekly Efficacy Research(TOWER)trial. Curr Med Res Opin, 29 : 195-203, 2013
- 19) Mori S, et al : Sequential therapy with once-weekly teriparatide injection followed by alendronate versus monotherapy with alendronate alone in patients at high risk of osteoporotic fracture : final results of the Japanese Osteoporosis Intervention Trial-05. Osteoporos Int, 2022(Online publication).
- 20) Cosman F, et al : Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med, 375 : 1532-1543, 2016
- 21) Lewiecki EM, et al : One Year of Romosozumab followed by two years of denosumab maintains fracture risk reductions : Results of the FRAME extension study. J Bone Miner Res, 34 : 419-428, 2019
- 22) Saag KG, et al : Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med, 377 : 1417-1427, 2017
- 23) Miller PD, et al : Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis : A randomized clinical trial. JAMA, 316 : 722-733, 2016
- 24) Bone HG, et al : ACTIVExtend : 24 months of alendronate after 18 months of abaloparatide or placebo for post-menopausal osteoporosis. J Clin Endocrinol Metab, 103 : 2949-2957, 2018
- 25) Curtis EM : Management of patients at very high risk of osteoporotic fractures through sequential treatments. Aging Clin Exp Res, 34 : 695-714, 2022
